ATS 2020 Advance Program

9:32 Cannabis and the Human Alveolar Macrophage S. Sharma, MD, MPH, Aurora, CO 9:49 Animal Models of Cannabis Use: Viral Infections N. Kaminski, PhD, East Lansing, MI 10:06 Cannabidiol (CBD) and the Airway Epithelium K.L. Bailey, MD, ATSF, Omaha, NE 10:24 Asthma and Cannabis Use A.P. Nayak, PhD, Philadelphia, PA 10:41 Airway Epithelial Cell Transcriptional Responses to Cannabis Smoke Exposure J.A. Hirota, PhD, BSc, Hamilton, Canada 10:58 Regulatory Issues Associated With Cannabis Research T.J. Witek, DrPH, ATSF, Toronto, Canada BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM C12 INITIATING PHARMACOLOGIC TREATMENT OF TOBACCO DEPENDENCE ACROSS THE SPECTRUM Assemblies on Behavioral and Health Services Research; Clinical Problems; Environmental, Occupational and Population Health; Nursing; Pediatrics; Thoracic Oncology; Tobacco Action Committee 9:15 a.m. - 11:15 a.m. Target Audience Physicians; nurses; allied health professionals; junior physicians. Objectives At the conclusion of this session, the participant will be able to: • review the research on the treatment of tobacco dependence; • understand how certain therapies and interventions can be tailored for tobacco dependence in the specific patient populations; • acquire insight for translating the recommendations into clinical practice. Tobacco dependence continues to be the greatest preventable risk factor for many morbidities, contributing to both the etiology of and worsening of many illnesses. While the management of tobacco dependence has gained considerable scientific attention and research over the last several decades, an updated review of pharmacological management for tobacco dependence is warranted. We will discuss the newest recommendations as set forth by the American Thoracic Society. These recommendations represent the most up to date evidence around pharmacological tactics to achieve smoking cessation. This session will touch on each important recommendations, discuss research gaps, and provide insight into the research data used to move from evidence to clinical decision. Chairing: P. Galiatsatos, DrMed, Baltimore, MD H. Kathuria, MD, ATSF, Boston, MA 9:15 What Comes After the 5A’s? Genesis and Structure of the ATS Tobacco Treatment Guideline F.T. Leone, MD, MS, ATSF, Philadelphia, PA 9:30 What Is the Grade Methodology? Y.M. Zhang, PhD, Hamilton, Canada 9:45 In Search of the Best Initial Controller: Varenicline or Nicotine Patch? Varenicline or Bupropion? J.T. Fathi, DNP, ARNP, CTTS, Seattle, WA 10:00 How Do We Enhance the Chance of Success? Best Controller Alone, or Combined With a Reliever? H. Gogineni, MS, PharmD, TTS, Pomona, CA 10:15 “But Doc, I’m Not Ready to Quit or It Is Not Working Yet.” When to Initiate and How Long Should You Treat S.P. Kantrow, MD, New Orleans, LA 10:30 Where Does the Electronic Cigarette Fit In? D.J. Upson, MD, MA, ATSF, Albuquerque, NM 10:45 But How Do I Make This Work in My Clinical Practice? P. Galiatsatos, DrMed, Baltimore, MD ATS 2020 • Philadelphia, PA 108 TUESDAY • MAY 19